Document is current
Any future updates will be listed below
-
Authors
Antozzi, Carlo https://orcid.org/0000-0001-9270-5224
Frangiamore, Rita https://orcid.org/0000-0002-0383-3791
Rinaldi, Elena https://orcid.org/0000-0003-0744-7238
Vanoli, Fiammetta https://orcid.org/0000-0002-9081-6462
Andreetta, Francesca https://orcid.org/0000-0001-8239-8830
Grigoli, Eleonora Giacopuzzi
Ciusani, Emilio https://orcid.org/0000-0002-7285-123X
Bonanno, Silvia https://orcid.org/0000-0002-8823-6821
Maggi, Lorenzo https://orcid.org/0000-0002-0932-5173
Mantegazza, Renato https://orcid.org/0000-0002-9810-5737
- License Information
-
More Information
Article History
Received: 24 November 2024
Accepted: 28 February 2025
First Online: 25 March 2025
Declarations
:
: The study was approved by the Institutional Review Board of the local hospital.
: C. Antozzi received funding for travel, meeting attendance and advisory board participation from Alexion, Momenta, Sanofi, Janssen, argenx and UCB. F. Vanoli received funding for travel, meeting attendance and consulting by Alexion Pharmaceuticals, UCB Pharma and Argenx. S. Bonanno received funding for travel, meeting attendance and advisory board participation from Sanofi Genzyme, Biogen, Alexion and Roche. R. Frangiamore received funding for travel, consulting, meeting attendance and advisory board participation by argenx, UCB, Alexion, Biogen, Sanofi Genzyme. L. Maggi received funding for travel, meeting attendance, honoraria for speaking and advisory board participation from Sanofi Genzyme, Roche, Biogen, Amicus Therapeutics, Alexion, UCB, argenx, Janssen, Lupin. R. Mantegazza received funding for travel, meeting attendance and advisory board participation from Alexion, argenx, Biomarin, Catalyst, Sanofy Genzyme, Regeneron and UCB. E. Rinaldi, F. Andreetta, E. Ciusani and E. Giacopuzzi have nothing to disclose.
